Nina Eissler

Company: Affibody AB

Job title: Director Translational Medicine

Seminars:

Exploring Affibody Molecules as Vehicles for Molecular Radiotherapy of HER2- expressing Malignancies: ABY-025 for Patient Selection & ABY-271 for Radioligand Therapy 12:15 pm

Selecting patients by immunohistochemistry has limitations and image-guided decisions have recently proven superior Using the PET tracer ABY-025 to demonstrate correlation with improved treatment response prediction and can be translated therapeutically using linker technology for improved kinetics ABY-271 is a candidate in late preclinical development for molecular radiotherapy of HER2 expressing cancersRead more

day: Day 2 - P&T Track AM